Home LiteratureArticle Details
PMID: 18047738 Published · epublish English Journal Article Review

Patented small molecule inhibitors in the ubiquitin proteasome system.

BMC biochemistry ·Vol. 8 Suppl 1 ·2007-11-22 ·Pages S14

Guédat P, Colland F

Abstract

Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(R) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

MeSH Terms
Animals Humans Nonprescription Drugs/chemistry,pharmacology Protease Inhibitors/chemistry,pharmacology Proteasome Endopeptidase Complex/metabolism Proteasome Inhibitors Ubiquitin-Protein Ligase Complexes/antagonists & inhibitors,metabolism
Chemicals
Nonprescription Drugs Protease Inhibitors Proteasome Inhibitors Ubiquitin-Protein Ligase Complexes Proteasome Endopeptidase Complex
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Guédat Philippe
Hybrigenics SA, 3-5 Impasse Reille, 75014 Paris, France. pguedat@hybrigenics.com
Colland Frédéric
References (57)
57 references, click to expand
  1. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo.
    J Biol Chem. 2001 Apr 20;276(16):13322-30 PMID: 11278274
  2. A uniform isopeptide-linked multiubiquitin chain is sufficient to target substrate for degradation in ubiquitin-mediated proteolysis.
    J Biol Chem. 1990 May 25;265(15):8354-7 PMID: 2160452
  3. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis.
    Proc Natl Acad Sci U S A. 1980 Apr;77(4):1783-6 PMID: 6990414
  4. Effects of exogenous ubiquitin in lethal endotoxemia.
    Surgery. 2004 May;135(5):536-43 PMID: 15118591
  5. Mechanisms underlying ubiquitination.
    Annu Rev Biochem. 2001;70:503-33 PMID: 11395416
  6. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
    Cell. 1990 Dec 21;63(6):1129-36 PMID: 2175676
  7. Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85.
    Cell. 1984 May;37(1):43-55 PMID: 6327059
  8. The proteasome, a novel protease regulated by multiple mechanisms.
    J Biol Chem. 1999 Aug 6;274(32):22123-6 PMID: 10428771
  9. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes.
    J Biol Chem. 1980 Aug 25;255(16):7525-8 PMID: 6249802
  10. Synthetic analogs of green tea polyphenols as proteasome inhibitors.
    Mol Med. 2002 Jul;8(7):382-92 PMID: 12393936
  11. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation.
    Proc Natl Acad Sci U S A. 1980 Mar;77(3):1365-8 PMID: 6769112
  12. Tumour suppression: disruption of HAUSP gene stabilizes p53.
    Nature. 2004 Apr 1;428(6982):1 p following 486 PMID: 15058298
  13. Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma.
    J Trauma. 2004 May;56(5):991-9; discussion 999-1000 PMID: 15179237
  14. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.
    Bioorg Med Chem Lett. 2005 Mar 1;15(5):1515-20 PMID: 15713419
  15. High-throughput screening for inhibitors of the e3 ubiquitin ligase APC.
    Methods Enzymol. 2005;399:740-54 PMID: 16338393
  16. RING finger proteins: mediators of ubiquitin ligase activity.
    Cell. 2000 Sep 1;102(5):549-52 PMID: 11007473
  17. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Cancer Cell. 2005 Nov;8(5):407-19 PMID: 16286248
  18. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain.
    Science. 2004 Oct 1;306(5693):117-20 PMID: 15459393
  19. Ubiquitin signalling in the NF-kappaB pathway.
    Nat Cell Biol. 2005 Aug;7(8):758-65 PMID: 16056267
  20. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis.
    Nat Rev Cancer. 2006 Oct;6(10):776-88 PMID: 16990855
  21. Proteasome inhibitors as therapeutic agents: current and future strategies.
    Curr Med Chem. 2003 Mar;10(6):479-503 PMID: 12570694
  22. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown.
    J Biol Chem. 1983 Jul 10;258(13):8206-14 PMID: 6305978
  23. Targeting proteases: successes, failures and future prospects.
    Nat Rev Drug Discov. 2006 Sep;5(9):785-99 PMID: 16955069
  24. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
    IDrugs. 2006 Mar;9(3):179-81 PMID: 16523381
  25. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
    Science. 2004 Feb 6;303(5659):844-8 PMID: 14704432
  26. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
    Cancer Cell. 2005 Jun;7(6):547-59 PMID: 15950904
  27. The roles of intracellular protein-degradation pathways in neurodegeneration.
    Nature. 2006 Oct 19;443(7113):780-6 PMID: 17051204
  28. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
    Nat Med. 2004 Dec;10(12):1321-8 PMID: 15558054
  29. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein.
    Science. 1989 Mar 24;243(4898):1576-83 PMID: 2538923
  30. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
    Cell. 1992 Jun 26;69(7):1237-45 PMID: 1535557
  31. Back to the future with ubiquitin.
    Cell. 2004 Jan 23;116(2):181-90 PMID: 14744430
  32. A dynamic role of HAUSP in the p53-Mdm2 pathway.
    Mol Cell. 2004 Mar 26;13(6):879-86 PMID: 15053880
  33. Thiol proteases: inhibitors and potential therapeutic targets.
    Curr Med Chem. 2006;13(5):547-81 PMID: 16515521
  34. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death.
    Mol Pharmacol. 2002 Aug;62(2):351-8 PMID: 12130688
  35. A genomic and functional inventory of deubiquitinating enzymes.
    Cell. 2005 Dec 2;123(5):773-86 PMID: 16325574
  36. Drug discovery in the ubiquitin-proteasome system.
    Nat Rev Drug Discov. 2006 Jul;5(7):596-613 PMID: 16816840
  37. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.
    Physiol Rev. 2002 Apr;82(2):373-428 PMID: 11917093
  38. A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
    Br J Cancer. 2006 Oct 23;95(8):961-5 PMID: 17047643
  39. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP.
    Nat Cell Biol. 2006 Oct;8(10):1064-73 PMID: 16964248
  40. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.
    PLoS Biol. 2006 Feb;4(2):e27 PMID: 16402859
  41. Targeting the monocytic ubiquitin system with extracellular ubiquitin.
    Immunol Cell Biol. 2006 Feb;84(1):59-65 PMID: 16277638
  42. The trans-Golgi network-associated human ubiquitin-protein ligase POSH is essential for HIV type 1 production.
    Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1478-83 PMID: 15659549
  43. p53 ubiquitination: Mdm2 and beyond.
    Mol Cell. 2006 Feb 3;21(3):307-15 PMID: 16455486
  44. Proteasome inhibitors: a novel class of potent and effective antitumor agents.
    Cancer Res. 1999 Jun 1;59(11):2615-22 PMID: 10363983
  45. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade.
    Nature. 1995 Jan 5;373(6509):81-3 PMID: 7800044
  46. Ubiquitin is a component of paired helical filaments in Alzheimer's disease.
    Science. 1987 Mar 27;235(4796):1641-4 PMID: 3029875
  47. The ubiquitin-proteasome pathway in viral infections.
    Can J Physiol Pharmacol. 2006 Jan;84(1):5-14 PMID: 16845885
  48. Identification of ubiquitin ligases required for skeletal muscle atrophy.
    Science. 2001 Nov 23;294(5547):1704-8 PMID: 11679633
  49. Structure-based design of potent non-peptide MDM2 inhibitors.
    J Am Chem Soc. 2005 Jul 27;127(29):10130-1 PMID: 16028899
  50. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.
    Cell. 1994 Sep 9;78(5):773-85 PMID: 8087845
  51. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases.
    Cell Mol Immunol. 2006 Aug;3(4):255-61 PMID: 16978533
  52. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway.
    J Biol Chem. 2001 Aug 10;276(32):30366-73 PMID: 11390388
  53. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain.
    Cell. 2000 Oct 13;103(2):351-61 PMID: 11057907
  54. Amplification of a gene encoding a p53-associated protein in human sarcomas.
    Nature. 1992 Jul 2;358(6381):80-3 PMID: 1614537
  55. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.
    J Med Chem. 2005 Feb 24;48(4):909-12 PMID: 15715460
  56. The proteasome: a suitable antineoplastic target.
    Nat Rev Cancer. 2004 May;4(5):349-60 PMID: 15122206
  57. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization.
    Mol Cell. 2005 Apr 1;18(1):25-36 PMID: 15808506
Article Info
Journal
BMC biochemistry
Abbr.
BMC Biochem
ISSN
1471-2091
DOI
10.1186/1471-2091-8-S1-S14
Email
pguedat@hybrigenics.com
Published
2007-11-22
Epub
2007-00-22
Pages
S14
Language
English
Region
England
NLM ID
101084098
PMCID
PMC2106365
Subset
IM
External Links
PubMed source DOI: 10.1186/1471-2091-8-S1-S14 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2